{"id":"vasopressin-early-initiation","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral vasoconstriction / ischemia"},{"rate":null,"effect":"Hyponatremia"},{"rate":null,"effect":"Coronary vasoconstriction"},{"rate":null,"effect":"Arrhythmias"}]},"_chembl":{"chemblId":"CHEMBL1201528","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vasopressin acts as a potent vasoconstrictor by activating V1 receptors on vascular smooth muscle cells, leading to increased systemic vascular resistance and blood pressure. Early initiation in septic shock aims to rapidly restore perfusion pressure and reduce the need for catecholamine vasopressors. The hormone also has antidiuretic effects through V2 receptor activation in the kidney, helping maintain fluid balance.","oneSentence":"Vasopressin is a naturally occurring hormone that binds to vasopressin receptors to increase blood pressure and vasoconstriction, used in early septic shock management to restore hemodynamic stability.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:14:47.995Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Septic shock (early initiation for hemodynamic support)"},{"name":"Variceal bleeding"}]},"trialDetails":[{"nctId":"NCT06709573","phase":"PHASE4","title":"Early Versus Late Adjunctive Vasopressin in Septic Shock","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-04-29","conditions":"Sepsis, Septic Shock","enrollment":300},{"nctId":"NCT06155812","phase":"PHASE2, PHASE3","title":"Multimodal Vasopressor Strategy in Septic Shock","status":"RECRUITING","sponsor":"University Medical Centre Maribor","startDate":"2023-12-23","conditions":"Shock, Septic","enrollment":80},{"nctId":"NCT00624650","phase":"PHASE2","title":"Hemodynamics and Extravascular Lung Water in Acute Lung Injury","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2008-02","conditions":"Acute Lung Injury","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["vasopressin"],"phase":"marketed","status":"active","brandName":"vasopressin - early initiation","genericName":"vasopressin - early initiation","companyName":"The Cleveland Clinic","companyId":"the-cleveland-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vasopressin is a naturally occurring hormone that binds to vasopressin receptors to increase blood pressure and vasoconstriction, used in early septic shock management to restore hemodynamic stability. Used for Septic shock (early initiation for hemodynamic support), Variceal bleeding.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}